CIK 0001861123 · <br>Emerging growth company
Eikon Therapeutics, Inc.
Sign in to watch- Ticker
- EIKN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 842807586
- Phone
- 341-777-0566
- Business address
- 230 HARRIET TUBMAN WAY, MILLBRAE, CA, 94030
- Open-market buys, last 90 days
- $1,031,045
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$1,031,045. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-03 | Column Group IV GP, LP 10% owner | Purchase | +89,200 | $11.56 | $1.0M | 89,200 |
| 2026-03-02 | Klobuchar Michael A Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +87,157 | 87,157 | ||
| 2026-03-02 | Huffines Robert Luther Director | Grant or award · Stock Option (Right to Buy) | +25,873 | 25,873 | ||
| 2026-03-02 | FRAZIER KENNETH C Director | Grant or award · Stock Option (Right to Buy) | +25,873 | 25,873 | ||
| 2026-03-02 | PERLMUTTER ROGER M See remarks | Grant or award · Stock Option (Right to Buy) | +268,176 | 268,176 | ||
| 2026-03-02 | Thorner Benjamin Bruno See Remarks | Grant or award · Stock Option (Right to Buy) | +67,044 | 67,044 | ||
| 2026-03-02 | Baynes Roy D. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +134,088 | 134,088 | ||
| 2026-03-02 | Bowie Alfred Lloyd Jr. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +67,044 | 67,044 | ||
| 2026-02-06 | PERLMUTTER ROGER M See remarks | Conversion | +284,857 | 284,857 | ||
| 2026-02-06 | PERLMUTTER ROGER M See remarks | Conversion · Series A-1 Preferred Stock | −1,268,891 | 0 | ||
| 2026-02-06 | PERLMUTTER ROGER M See remarks | Conversion · Series D Preferred Stock | −855,512 | 0 | ||
| 2026-02-06 | Column Group IV GP, LP 10% owner | Conversion | +1,296,629 | 1,360,320 | ||
| 2026-02-06 | Column Group IV GP, LP 10% owner | Conversion | +1,403,568 | 2,763,888 | ||
| 2026-02-06 | Column Group IV GP, LP 10% owner | Conversion | +110,928 | 2,874,816 | ||
| 2026-02-06 | Column Group IV GP, LP 10% owner | Conversion | +44,249 | 47,601 | ||
| 2026-02-06 | Column Group IV GP, LP 10% owner | Conversion | +47,898 | 95,499 | ||
| 2026-02-06 | Column Group IV GP, LP 10% owner | Conversion | +3,785 | 99,284 | ||
| 2026-02-06 | Column Group IV GP, LP 10% owner | Conversion | +688,283 | 688,283 | ||
| 2026-02-06 | Column Group IV GP, LP 10% owner | Purchase | +1,437,323 | $18.00 | $25.9M | 4,312,139 |
| 2026-02-06 | Column Group IV GP, LP 10% owner | Purchase | +49,556 | $18.00 | $892K | 148,840 |
Page 1 of 5 · 88 trades